医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Epidemiology: Inflammatory Bowel Disease – Early diagnosis and improved survival lead to increased patient populations

2012年09月26日 AM02:17
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/kmdx39/epidemiology) has announced the addition of the “Epidemiology: Inflammatory Bowel Disease – Early diagnosis and improved survival lead to increased patient populations” report to their offering.

Inflammatory bowel diseases (IBDs) are mainly composed of three chronic diseases; Crohn’s disease, ulcerative colitis, and indeterminate colitis. Although the etiology of inflammatory bowel disease is largely unknown, the incidence of IBD has substantially increased in the past decade.

Gain insight into market potential, including a robust 10-year epidemiology forecast of Crohn’s disease and ulcerative colitis prevalent cases.Gain insights into the current and future prevalent trends of Crohn’s disease and ulcerative colitis in the next 10 years.Understand the key epidemiologic risk factors associated with inflammatory bowel diseases.Since the 1950s, the overall incidence of IBD has gradually increased, although the increase in the incidence of ulcerative colitis (UC) precedes the increase in Crohn’s disease (CD) by approximately 15-20 years.

Across the seven major markets, Datamonitor estimates that in 2011 there were approximately 913,000 and 1.7 million prevalent cases of Crohn’s disease and ulcerative colitis, respectively.Between 2011 and 2021, Datamonitor estimates that prevalent cases of both Crohn’s disease and ulcerative colitis will increase.How will the IBD patient population change over the next decade in the seven major markets?What are the estimated prevalent cases of Crohn’s disease and ulcerative colitis in the seven major markets?

Key Topics Covered:

– OVERVIEW

– EXECUTIVE SUMMARY

– DISEASE DEFINITION AND DIAGNOSIS CRITERIA

– GLOBAL VARIATION AND HISTORICAL TRENDS

– RISK FACTORS

– EPIDEMIOLOGIC FORECASTING OF INFLAMMATORY BOWEL DISEASE

– EPIDEMIOLOGIC RESULTS

– DISCUSSION

– BIBLIOGRAPHY

– TABLES

FIGURES

Companies Mentioned

– Bull

– Hutchison 3G UK Limited

– Metro AG

– Schindler Holding Ltd.

For more information visit http://www.researchandmarkets.com/research/kmdx39/epidemiology

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

同じカテゴリーの記事 

  • 卫材启用Medidata Clinical Data Studio推进临床试验效率和患者体验的革新
  • Fujirebio推出研究专用全自动Lumipulse®G GFAP检测试剂盒并进一步强化该公司的神经病学产品阵容
  • Fujirebio Launches the Fully Automated Lumipulse® G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu
  • Pearl、歯科AIで史上最大5,800万ドルの資金調達ラウンドを実施
  • FIGS Announces Date of Second Quarter 2024 Earnings Release, Conference Call and Webcast